Latest Breaking News On - Oramed pharmaceuticals daily - Page 3 : comparemela.com

Oramed Pharmaceuticals Inc (NASDAQ:ORMP) Expected to Earn Q1 2024 Earnings of $0 02 Per Share

Oramed Pharmaceuticals Inc (NASDAQ:ORMP) Expected to Earn Q1 2024 Earnings of $0 02 Per Share
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesAmerican century companies incAlgert globalOramed pharmaceuticals stockOramed pharmaceuticals incOramed pharmaceuticalsNews ratings for oramed pharmaceuticals dailyQube research technologies ltdRathbones groupFree reportOramed pharmaceuticalGet free reportCentury companiesTechnologies ltdPharmaceuticals incOramed pharmaceuticals daily

Short Interest in Oramed Pharmaceuticals Inc (NASDAQ:ORMP) Declines By 25 9%

Short Interest in Oramed Pharmaceuticals Inc (NASDAQ:ORMP) Declines By 25 9%
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Hong kongOramed pharmaceuticalsRenaissance technologiesOramed pharmaceuticals company profileTower research capitalOramed pharmaceuticals incNews ratings for oramed pharmaceuticals dailyOramed pharmaceuticals price performanceHong kong ltdInstitutional trading of oramed pharmaceuticalsGet free reportKong ltdResearch capitalJacobson investment advisorsPharmaceuticals incOramed pharmaceuticals daily

Oramed Pharmaceuticals Inc (NASDAQ:ORMP) Sees Significant Decrease in Short Interest

Oramed Pharmaceuticals Inc (NASDAQ:ORMP) Sees Significant Decrease in Short Interest
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Belpointe asset managementOramed pharmaceuticals tradingJanney montgomery scottOramed pharmaceuticalsRussell investments group ltdNews ratings for oramed pharmaceuticals dailyOramed pharmaceuticals incOramed pharmaceuticals company profileInstitutional investors weigh in on oramed pharmaceuticalsGet free reportInvestments groupMontgomery scottAsset managementGlass jacobson investment advisorsPharmaceuticals incOramed pharmaceuticals daily

Oramed Pharmaceuticals Inc (NASDAQ:ORMP) Sees Significant Decrease in Short Interest

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Free Report) was the recipient of a significant drop in short interest in July. As of July 15th, there was short interest totalling 677,000 shares, a drop of 15.1% from the June 30th total of 797,800 shares. Based on an average trading volume of 869,200 shares, the days-to-cover ratio […]

Hong kongUnited statesHong kong ltdWells fargo companyOramed pharmaceuticals stock performanceOramed pharmaceuticalsNews ratings for oramed pharmaceuticals dailyAmerican international group incOramed pharmaceuticals incInstitutional trading of oramed pharmaceuticalsGet free reportInternational groupKong ltdStreet corpWells fargoPharmaceuticals inc

Landscape Capital Management L L C Acquires New Stake in Oramed Pharmaceuticals Inc (NASDAQ:ORMP)

Landscape Capital Management L.L.C. acquired a new position in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 26,220 shares of the biotechnology company’s stock, valued at approximately $315,000. Landscape Capital Management L.L.C. owned […]

Yadin rozovNadav kidronRenaissance technologiesOramed pharmaceuticalsQuarter for oramed pharmaceuticalsOramed pharmaceuticals profileMillennium managementBlackrock incOramed pharmaceuticals incSecurities exchange commissionLindbrook capitalOramed pharmaceuticals trading downNews ratings for oramed pharmaceuticals dailyGet ratingStreet corpDirector yadin rozov